C4XD and AstraZeneca Ink Licensing Deal
C4X Discovery and AstraZeneca have inked a licensing deal for C4XD’s NRF2 Activator program to develop and market an oral therapy for inflammatory and respiratory diseases, focusing on chronic obstructive pulmonary disease (COPD).
NRF2 (nuclear factor-erythroid factor 2-related factor 2) is considered a crucial regulator of antioxidant defense, providing an anti-inflammatory response to protect organs damaged by injury or illness.
Using NRF2 to reduce inflammatory damage “offers the potential for a new approach to treat a variety of inflammatory diseases such as COPD, where activation of NRF2 may help in reducing the negative effects of the oxidative stress-induced progression of the disease,” the company said.
C4XD will receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. The company is also eligible for a potential $385.8 million if it meets clinical development and commercial milestones, as well as royalties on sales.